AREV Life Sciences Global Corp
CNSX:AREV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (5.1), the stock would be worth CA$-0.06 (163% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -8.1 | CA$0.09 |
0%
|
| Industry Average | 5.1 | CA$-0.06 |
-163%
|
| Country Average | 10.2 | CA$-0.11 |
-226%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
A
|
AREV Life Sciences Global Corp
CNSX:AREV
|
2.9m CAD | -8.1 | -9 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
309.8B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | 3 417.4 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
102.5B ZAR | 14.4 | 10.6 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
68B USD | -17 989.5 | 38 417.9 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
58.9B USD | 0 | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
35.4B CHF | 0 | 0 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
37.6B USD | -4 589.1 | -3 457.1 | |
| US |
|
Coupang Inc
F:788
|
31.7B EUR | 32.1 | 175.5 | |
| US |
R
|
Reddit Inc
NYSE:RDDT
|
29.2B USD | 58.4 | 55.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 7 |
| Median | 10.2 |
| 70th Percentile | 14.5 |
| Max | 13 731.1 |
Other Multiples
AREV Life Sciences Global Corp
Glance View
AREV Life Sciences Global Corp. engages in the production and development of natural health and cannabis infused products. The company is headquartered in Coquitlam, British Columbia. The company went IPO on 2007-07-12. The firm focuses on delivering solutions to public healthcare metrics through collaborations in the life science industry. Its initial business is to produce and sell functional ingredients produced through its extraction systems. These ingredients and products are targeted at the natural health, medical, functional food, nutraceutical, sport nutrition markets. Its technologies enable the extraction of targeted essential and functional oils from target biomass, including hemp, create formulations combining cannabidiol (CBD) with these extracted oils or powders offered in various delivery methods, such as gel caps in branded formats for consumer markets. The company offers nutraceutical products, ready to use therapeutic food products (RUTF's) and therapeutic drug discovery. Its subsidiaries include AREV (Cambodia) Brands Co., Ltd. and AREV Life Sciences Inc.
